Article
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
Alimentary pharmacology & therapeutics - 1 Mar 2012
Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster G R, Fox R, Hayes P C, Leen C, Mills P R, Mutimer D J, Ryder S D, Dillon J F
Abstract excerpt
BACKGROUND: The nonstructural 3 serine protease inhibitors (PIs), boceprevir and telaprevir, represent the first in a new generation of directly acting antivirals against genotype 1 hepatitis C (HCV) infection. When used in combination with pegylated interferon and ribavirin, these drugs greatly improve sustained virological response rates in both treatment-naïve patients and patients who have had previous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.